Search research articles
Contact Us
Filters
Showing results (61-70 of 83) with videos related to
Page
of 9
Sort By:
Experimental Cell Research
|
May 8, 2020
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia
Cheng Chen, Li Wang, Lili Li, et al.
Advanced Materials (Deerfield Beach, Fla.)
|
April 27, 2026
Fluoroacetate-Mediated Dual-Interface Ionic Stabilization in Perovskite Solar Cells
Huitian Guo, Fengchun Cai, Lianyou Tang, et al.
Plos One
|
February 26, 2013
Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells
Ellen Weisberg, Qingsong Liu, Xin Zhang, et al.
Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences
|
May 11, 2022
Diagnosis and treatment of multiple myeloma in Hunan Province
Feiyang Liu, Qian Cheng, Kui Song, et al.
Scientific Reports
|
August 6, 2024
Quantum modeling simulates nutrient effect of bioplastic polyhydroxyalkanoate (PHA) production in Pseudomonas putida
Lawrence Yuk Lung Ho, Li Pan, Fei Meng, et al.
Journal of Medicinal Chemistry
|
April 15, 2016
Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)
Qiang Wang, Feiyang Liu, Beilei Wang, et al.
ACS Chemical Biology
|
April 16, 2016
Discovery of a Highly Selective STK16 Kinase Inhibitor
Feiyang Liu, Jinhua Wang, Xingxing Yang, et al.
Journal of Medicinal Chemistry
|
June 29, 2019
Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors
Yun Wu, Beilei Wang, Junjie Wang, et al.
Journal of Medicinal Chemistry
|
December 15, 2016
Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding
Qiang Wang, Feiyang Liu, Beilei Wang, et al.
ACS Chemical Biology
|
August 1, 2013
Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor
Hyung-Gu Kim, Li Tan, Ellen L Weisberg, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 83) with videos related to
Sort By:
Page
of 9
Experimental Cell Research
|
May 8, 2020
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia
Cheng Chen, Li Wang, Lili Li, et al.
Advanced Materials (Deerfield Beach, Fla.)
|
April 27, 2026
Fluoroacetate-Mediated Dual-Interface Ionic Stabilization in Perovskite Solar Cells
Huitian Guo, Fengchun Cai, Lianyou Tang, et al.
Plos One
|
February 26, 2013
Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells
Ellen Weisberg, Qingsong Liu, Xin Zhang, et al.
Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences
|
May 11, 2022
Diagnosis and treatment of multiple myeloma in Hunan Province
Feiyang Liu, Qian Cheng, Kui Song, et al.
Scientific Reports
|
August 6, 2024
Quantum modeling simulates nutrient effect of bioplastic polyhydroxyalkanoate (PHA) production in Pseudomonas putida
Lawrence Yuk Lung Ho, Li Pan, Fei Meng, et al.
Journal of Medicinal Chemistry
|
April 15, 2016
Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)
Qiang Wang, Feiyang Liu, Beilei Wang, et al.
ACS Chemical Biology
|
April 16, 2016
Discovery of a Highly Selective STK16 Kinase Inhibitor
Feiyang Liu, Jinhua Wang, Xingxing Yang, et al.
Journal of Medicinal Chemistry
|
June 29, 2019
Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors
Yun Wu, Beilei Wang, Junjie Wang, et al.
Journal of Medicinal Chemistry
|
December 15, 2016
Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding
Qiang Wang, Feiyang Liu, Beilei Wang, et al.
ACS Chemical Biology
|
August 1, 2013
Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor
Hyung-Gu Kim, Li Tan, Ellen L Weisberg, et al.
Page
of 9